SYSTIMMUNE

SystImmune expands its iza-bren programme again | ApexOnco - Clinical Trials news and analysis

Oncology Pipeline · 1 day ago

SystImmune starts another first-line phase 3 | ApexOnco - Clinical Trials news and analysis

Oncology Pipeline · about 1 month ago

SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026

PR Newswire · 2 months ago

Systimmune’s iza-bren hits phase III breast cancer goals in China

BioWorld News · 3 months ago

Bristol Myers, SystImmune post late-stage trial win for breast cancer drug

Seeking Alpha · 3 months ago

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast ...

Business Wire · 3 months ago

SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO

PR Newswire · 7 months ago

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025

PR Newswire · 7 months ago

SystImmune to Receive $250M BMS Milestone

Contract Pharma · 7 months ago

SystImmune receives $250 million milestone payment from Bristol Myers Squibb

Investing.com · 7 months ago

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

PR Newswire · 7 months ago

SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform

PR Newswire · 8 months ago

SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025

PR Newswire · 9 months ago

FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug

Pharmaceutical Technology · 9 months ago

Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan...

Medical Dialogues · 9 months ago

SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations at ASCO Congress ...

PR Newswire · 12 months ago

SystImmune, Inc. to Present Updated izalontamab brengitecan (iza-bren) Data in Locally Advanced or Metastatic Breast Cancer at ESMO Breast 2025

PR Newswire · about 1 year ago

Bristol goes pivotal with SystImmune-partnered conjugate | ApexOnco - Clinical Trials news and analysis

Oncology Pipeline · about 1 year ago